USD 1.44
(-16.76%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.73 USD | 42.14% |
2022 | -29.90 USD | -2633.9% |
2021 | 1.18 USD | 636.36% |
2020 | -0.22 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -1.08 USD | 31.03% |
2024 Q1 | -2.03 USD | -103.0% |
2023 Q4 | -1.00 USD | 29.08% |
2023 FY | - USD | 42.14% |
2023 Q3 | -1.41 USD | 67.36% |
2023 Q2 | -4.32 USD | -92.0% |
2023 Q1 | -2.25 USD | 14.12% |
2022 Q1 | 0.51 USD | -65.77% |
2022 Q4 | -2.62 USD | -1478.95% |
2022 Q3 | 0.19 USD | -86.9% |
2022 FY | - USD | -2633.9% |
2022 Q2 | 1.45 USD | 184.31% |
2021 Q3 | -0.29 USD | 0.0% |
2021 FY | - USD | 636.36% |
2021 Q4 | 1.49 USD | 613.79% |
2020 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
AIM ImmunoTech Inc. | -0.60 USD | -188.333% |
Ampio Pharmaceuticals, Inc. | -10.67 USD | 83.786% |
Armata Pharmaceuticals, Inc. | -1.91 USD | 9.424% |
Actinium Pharmaceuticals, Inc. | -1.83 USD | 5.464% |
Azitra, Inc. | -54.76 USD | 96.841% |
Can-Fite BioPharma Ltd. | -1.79 USD | 3.352% |
Chromocell Therapeutics Corporation | -1.28 USD | -35.156% |
CEL-SCI Corporation | -0.73 USD | -136.986% |
iBio, Inc. | -6.50 USD | 73.385% |
Lineage Cell Therapeutics, Inc. | -0.12 USD | -1341.667% |
MAIA Biotechnology, Inc. | -1.49 USD | -16.107% |
Matinas BioPharma Holdings, Inc. | -5.28 USD | 67.235% |
Navidea Biopharmaceuticals, Inc. | -0.59 USD | -193.22% |
NovaBay Pharmaceuticals, Inc. | -138.65 USD | 98.752% |
NanoViricides, Inc. | -0.70 USD | -147.143% |
Oragenics, Inc. | -9.18 USD | 81.155% |
BiomX Inc. | -5.10 USD | 66.078% |
BiomX Inc. | -5.10 USD | 66.078% |
Protalix BioTherapeutics, Inc. | 0.12 USD | 1541.667% |
Palatin Technologies, Inc. | -2.02 USD | 14.356% |
Scorpius Holdings, Inc. | -347.20 USD | 99.502% |